Study #2017-0027
A Phase 1/2, First-in-Human, Dose Escalation Study of MGD006, a CD123 x CD3 Dual Affinity Re-Targeting (DART) Bi-Specific Antibody-Based Molecule, in Patients with Relapsed or Refractory Acute Myeloid Leukemia or Intermediate-2/High Risk Myelodysplastic Syndrome
Study Status
Open
Treatment Agent
MGD006 (S80880)
Principal Investigator
Farhad Ravandi-Kashani
Description
The goal of this clinical study is to find the highest tolerable dose and recommended schedule of MGD006 that can be given to patients with acute myeloid leukemia (AML) . Acute myeloid leukemia is a cancer of the blood and bone marrow. The safety and efficacy of the study drug will also be studied. Researchers also want to learn about the side effects of MGD006, how much of the study drug gets into the blood stream, and how long the body takes to get rid of it.
General Information
Disease Group: Malignant neoplasms stated as primary lymphoid haematopoietic
Treatment Agent: MGD006 (S80880)
Treatment Location: Both at MD Anderson & Other Sites
Sponsor: I.R.I.S. (Institut de Recherches Internationales Servier),MacroGenics, Inc
Study Status
IRB Review and Approval Date: 02/12/2018
Recruitment Status: Open
Projected Accrual: 179
Resources and Links
Information and next steps
Disease:
Malignant neoplasms stated as primary lymphoid haematopoietic
Study phase:
Phase I
Physician name:
Farhad Ravandi-Kashani
Department:
Cancer Medicine
For general questions about clinical trials:
1-877-632-6789